JP2017503756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503756A5 JP2017503756A5 JP2016533116A JP2016533116A JP2017503756A5 JP 2017503756 A5 JP2017503756 A5 JP 2017503756A5 JP 2016533116 A JP2016533116 A JP 2016533116A JP 2016533116 A JP2016533116 A JP 2016533116A JP 2017503756 A5 JP2017503756 A5 JP 2017503756A5
- Authority
- JP
- Japan
- Prior art keywords
- muscle activity
- treatment
- deuterium
- abnormal muscle
- structural formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907675P | 2013-11-22 | 2013-11-22 | |
| US61/907,675 | 2013-11-22 | ||
| PCT/US2014/066740 WO2015077520A1 (en) | 2013-11-22 | 2014-11-21 | Methods of treating abnormal muscular activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017503756A JP2017503756A (ja) | 2017-02-02 |
| JP2017503756A5 true JP2017503756A5 (OSRAM) | 2018-01-11 |
Family
ID=53180159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533116A Pending JP2017503756A (ja) | 2013-11-22 | 2014-11-21 | 異常な筋活動を処置する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160303110A1 (OSRAM) |
| EP (1) | EP3071565A4 (OSRAM) |
| JP (1) | JP2017503756A (OSRAM) |
| CA (1) | CA2930167A1 (OSRAM) |
| HK (1) | HK1224294A1 (OSRAM) |
| IL (1) | IL245538A0 (OSRAM) |
| MX (1) | MX2016006622A (OSRAM) |
| WO (1) | WO2015077520A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6362601B2 (ja) | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2930744A1 (en) | 2013-12-03 | 2015-06-11 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
| EP2918266A1 (en) * | 2014-03-11 | 2015-09-16 | CDRD Berolina AB | Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease |
| IL288712B2 (en) | 2015-03-06 | 2024-01-01 | Auspex Pharmaceuticals Inc | Methods for the treatment of abnormal involuntary movement disorders |
| WO2017180794A1 (en) | 2016-04-13 | 2017-10-19 | Skyline Antiinfectives, Inc. | Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams |
| US10786202B2 (en) | 2016-09-28 | 2020-09-29 | International Business Machines Corporation | Quantifying grip strength and characterizing movement idioms |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7367953B2 (en) * | 2003-11-26 | 2008-05-06 | Ge Medical Systems Global Technology Company | Method and system for determining a period of interest using multiple inputs |
| BRPI0708071A8 (pt) * | 2006-02-17 | 2017-12-26 | Birds Pharma Gmbh Berolina Innovative Res & Development Services | Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos |
| BRPI0711481A8 (pt) * | 2006-05-02 | 2017-11-28 | Univ Michigan Regents | derivados radiomarcados de dihidrotetrabenzeno e seu uso como agente de imagens |
| US8008500B2 (en) * | 2007-06-08 | 2011-08-30 | General Electric Company | Intermediates useful for making tetrabenazine compounds |
| KR101742668B1 (ko) * | 2008-06-12 | 2017-06-01 | 골지 피티와이 리미티드 | 운동부족 및/또는 운동과잉 상태의 검출 |
| US11016104B2 (en) * | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| EP3345905B1 (en) * | 2008-09-18 | 2021-09-01 | Auspex Pharmaceuticals, Inc. | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| US9676810B2 (en) * | 2010-07-08 | 2017-06-13 | The Brigham And Women's Hospital, Inc. | Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules |
| US9901564B2 (en) * | 2012-03-23 | 2018-02-27 | Cardero Therapeutics, Inc. | Compounds and compositions for the treatment of muscular disorders |
-
2014
- 2014-11-21 CA CA2930167A patent/CA2930167A1/en not_active Abandoned
- 2014-11-21 JP JP2016533116A patent/JP2017503756A/ja active Pending
- 2014-11-21 MX MX2016006622A patent/MX2016006622A/es unknown
- 2014-11-21 WO PCT/US2014/066740 patent/WO2015077520A1/en not_active Ceased
- 2014-11-21 HK HK16112663.3A patent/HK1224294A1/zh unknown
- 2014-11-21 EP EP14864919.7A patent/EP3071565A4/en not_active Withdrawn
- 2014-11-21 US US15/037,465 patent/US20160303110A1/en not_active Abandoned
-
2016
- 2016-05-08 IL IL245538A patent/IL245538A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503756A5 (OSRAM) | ||
| NZ721645A (en) | Compounds for use as gpr120 agonists | |
| BRPI0821994B8 (pt) | composto ou um enantiômero, um diasteroisômero ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto | |
| JP2012526791A5 (OSRAM) | ||
| EA201590520A1 (ru) | Фармацевтическая композиция с покрытием, содержащая регорафениб | |
| CL2013001558A1 (es) | El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico. | |
| FI3738434T3 (fi) | Välituotteita substituoitujen bentsaldehydiyhdisteiden saamiseksi ja menetelmiä niiden käyttöön kudosten hapetuksen lisäämiseksi | |
| JOP20180113B1 (ar) | مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية | |
| HRP20191617T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| ES2560676T3 (es) | Combinación farmacéutica para el tratamiento del dolor | |
| JP2015513557A5 (OSRAM) | ||
| MY189770A (en) | Biaryl derivative as gpr120 agonists | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| BR112014005389A8 (pt) | Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal | |
| PE20160874A1 (es) | Compuestos quimicos | |
| WO2016012965A3 (en) | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof | |
| MX377202B (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| RU2008139315A (ru) | Избирательные андрогенные рецепторные модуляторы | |
| MX2016007056A (es) | Metodos para preparar compuestos de benzoquinolina. | |
| EA201071099A1 (ru) | СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR | |
| EA201590735A1 (ru) | 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств | |
| BR112018006866A2 (pt) | compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos | |
| BR112022008786A2 (pt) | Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose | |
| EA201591804A1 (ru) | Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы | |
| BR112018001534A2 (pt) | inibidor de isocitrato desidrogenase idh1 r132h mutante |